- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06101095
En studie som utvärderar esofagusfunktion och ombyggnad med Dupilumab jämfört med placebo i 24 veckor följt av 104 veckors öppen märkning hos vuxna deltagare med EoE (ombyggnad med Dupilumab i eosinofil esofagit långtidsförsök)
En fas 4, randomiserad, multicenter, dubbelblind, parallellgrupp, 24 veckor, placebokontrollerad studie följt av 104 veckors öppen märkning för att bedöma Dupilumabs effekt på esofagusfunktion och ombyggnad hos vuxna deltagare med eosinofil esofagit (EoE)
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis.
Duration of study period (per participant)
- Screening period: Up to 12 weeks before Week 0
- Randomized double-blind period: 24 weeks
- Open label period: 104 weeks
- Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first.
There will be ten (10) site visits, and five (5) direct-to-participant IMP delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. In this case, IMP will be dispensed at the study site).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The duration per participant will be up to 152 weeks.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
-
São Paulo, Brasilien, 01323-020
- Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760003
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 41825-010
- Itaigara Memorial - Hospital Dia- Site Number : 0760005
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90610-000
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760006
-
-
São Paulo
-
Campinas, São Paulo, Brasilien, 13010-001
- Clínica Loema - Unidade I- Site Number : 0760007
-
Sorocaba, São Paulo, Brasilien, 18040-425
- Clinica de Alergia Martti Antila- Site Number : 0760001
-
-
-
-
California
-
Murrieta, California, Förenta staterna, 92563
- United Gastroenterologists - Murrieta- Site Number : 8400001
-
San Francisco, California, Förenta staterna, 94143
- University of California San Francisco - Parnassus Heights- Site Number : 8400020
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32256
- Borland Groover Clinic- Site Number : 8400016
-
-
Idaho
-
Boise, Idaho, Förenta staterna, 83706
- Treasure Valley Medical Research- Site Number : 8400018
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Northwestern University- Site Number : 8400003
-
Glenview, Illinois, Förenta staterna, 60026
- GI Alliance - Glenview- Site Number : 8400012
-
Gurnee, Illinois, Förenta staterna, 60031
- Illinois Gastroenterology Group- Site Number : 8400004
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52242
- University of Iowa- Site Number : 8400006
-
-
Massachusetts
-
Worcester, Massachusetts, Förenta staterna, 01655
- University of Massachusetts Chan Medical School- Site Number : 8400019
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Mayo Clinic Hospital Rochester- Site Number : 8400008
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27514
- University of North Carolina at Chapel Hill- Site Number : 8400007
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44195
- Cleveland Clinic - Cleveland- Site Number : 8400009
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Penn Medicine: University of Pennsylvania Health System- Site Number : 8400010
-
-
Texas
-
Houston, Texas, Förenta staterna, 77087
- Private Practice - Dr. Martin Yudovich- Site Number : 8400015
-
Mansfield, Texas, Förenta staterna, 76063
- GI Alliance - Mansfield- Site Number : 8400017
-
-
-
-
-
Haifa, Israel, 3104802
- Investigational Site Number : 3760006
-
Haifa, Israel, 3109601
- Investigational Site Number : 3760002
-
Jerusalem, Israel, 9103102
- Investigational Site Number : 3760005
-
Jerusalem, Israel, 9112001
- Investigational Site Number : 3760004
-
Tel Aviv, Israel, 6423906
- Investigational Site Number : 3760003
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Investigational Site Number : 1240006
-
Vancouver, British Columbia, Kanada, V6Z 2K5
- Investigational Site Number : 1240004
-
-
Quebec
-
Montreal, Quebec, Kanada, H4A 3T2
- Investigational Site Number : 1240002
-
-
-
-
-
Wetzikon, Schweiz, 8620
- Investigational Site Number : 7560001
-
Zurich, Schweiz, 8091
- Investigational Site Number : 7560002
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- A documented diagnosis of EoE by endoscopic biopsy.
- Baseline endoscopic biopsies with a demonstration on central reading of intraepithelial eosinophilic infiltration.
- History (by participant report) of an average of at least 2 episodes of dysphagia (with intake of solids) per week in the 4 weeks prior to screening.
- Body weight ≥40 kg.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Other causes of esophageal eosinophilia or the following conditions: hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome).
- Active Helicobacter pylori infection.
- History of achalasia, Crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery.
- Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to10 mm upper endoscope or any critical esophageal stricture that requires dilation at screening.
- History of bleeding disorders or esophageal varices.
- Treatment with swallowed topical corticosteroids within 8 weeks prior to baseline.
- Initiation or change of a food elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to screening.
- Participation in prior dupilumab clinical study or participants currently treated or have been treated with commercially available dupilumab or contraindicated to dupilumab per local labelling.
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
SC injection as per protocol |
SC injection as per protocol |
|
Experimentell: Dupilumab
Subcutaneous injection (SC) as per protocol |
Subcutaneous injection (SC) as per protocol |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe (EndoFLIP)
Tidsram: From baseline to Week 24
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline to Week 24
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidensen av behandlingsuppkomna biverkningar (TEAE) och allvarliga biverkningar (SAE)
Tidsram: Från den första administreringen av IMP till slutet av uppföljningsperioden efter behandling (vecka 139)
|
Från den första administreringen av IMP till slutet av uppföljningsperioden efter behandling (vecka 139)
|
|
|
Förekomst av biverkningar av särskilt intresse (AESI)
Tidsram: Från den första administreringen av IMP till slutet av uppföljningsperioden efter behandling (vecka 139)
|
Från den första administreringen av IMP till slutet av uppföljningsperioden efter behandling (vecka 139)
|
|
|
Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Tidsram: From baseline up to Week 24
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline up to Week 24
|
|
Absolute change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Tidsram: From baseline up to Week128
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline up to Week128
|
|
Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Tidsram: From Baseline up to Week 128
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From Baseline up to Week 128
|
|
Change from baseline in eosinophilic esophagitis-endoscopic reference score (EoE-EREFS)
Tidsram: From baseline up to Week 128
|
EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease. |
From baseline up to Week 128
|
|
Change from baseline in eosinophilic esophagitis (EoE-HSS) Grade
Tidsram: From Baseline up to Week 128
|
Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities. |
From Baseline up to Week 128
|
|
Change from baseline in EoE-HSS Stage
Tidsram: From Baseline up to Week 128
|
Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities. |
From Baseline up to Week 128
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤6 eosinophils/high power field (Eos/HPF)
Tidsram: At Weeks 24, 76 and 128
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Weeks 24, 76 and 128
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤15 Eos/HPF
Tidsram: At Week 24
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Week 24
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/HPF
Tidsram: At Weeks 24, 76 and 128
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Weeks 24, 76 and 128
|
|
Change from baseline in normalized enrichment score (NES) for EoE diagnostic panel (EDP) transcriptome signature
Tidsram: From baseline up to Week 128 (EOT)
|
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease). |
From baseline up to Week 128 (EOT)
|
|
Change from baseline in normalized enrichment score (NES) for type 2 inflammation transcriptome signature
Tidsram: From Baseline up to Week 128 (EOT)
|
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease). |
From Baseline up to Week 128 (EOT)
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studierektor: Clinical Sciences & Operations, Sanofi
Publikationer och användbara länkar
Allmänna publikationer
- Dellon ES, Carlson DA, Greuter T, Collins MH, Lankarani A, Talreja N, Ravi K, Simoes Neto J, Afif W, Gonsalves NP, Lynch KL, Zaghloul S, Cunoosamy D, Durrani SR, Zhang M, Raphael BP, Angello JT, Radwan A, Almansa C, Biedermann L. Dupilumab Improves Esophageal Distensibility in EoE: 24-Week Results From the REMODEL Randomized Trial. Am J Gastroenterol. 2026 Oct 12. doi: 10.14309/ajg.0000000000004227. Online ahead of print.
- Dellon ES, Savarino EV, Zaghloul S, Angello JT, Zhang M, Raphael BP, Radwan A, Bredenoord AJ. Study design of the phase IV, randomized, placebo-controlled REMOdeling with Dupilumab in Eosinophilic esophagitis Long-term (REMODEL) trial. Ther Adv Gastroenterol. 2025 Oct 9;18:17562848251383782. doi: 10.1177/17562848251383782. eCollection 2025.
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- LPS17558
- U1111-1280-5266 (Registeridentifierare: ICTRP)
- 2022-502491-23 (Registeridentifierare: CTIS)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .